Since then, several PD-L1/PD-1 blocking antibodies have been approved by the Food and Drug Administration (FDA) for many cancers, which include the PD-1 inhibitors nivolumab, pembrolizumab, cemiplimab and dostarlimab, and the PD-L1 inhibitors atezolizumab, durvalumab and avelumab (Table 1). Here, CD274 is linked to cancer.